Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Guardant Health, Inc. (NASDAQ:GH) has received a consensus rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $36.91.

A number of equities analysts have recently commented on GH shares. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. The Goldman Sachs Group lowered their price objective on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, April 15th. Piper Sandler lowered their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. Stephens reiterated an “overweight” rating and issued a $44.00 price objective on shares of Guardant Health in a research report on Friday, May 24th. Finally, Canaccord Genuity Group lifted their price objective on shares of Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GH. Rhumbline Advisers grew its holdings in shares of Guardant Health by 5.8% during the 3rd quarter. Rhumbline Advisers now owns 159,660 shares of the company’s stock worth $4,732,000 after purchasing an additional 8,688 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Guardant Health by 201.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 170,734 shares of the company’s stock worth $5,061,000 after purchasing an additional 114,128 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Guardant Health during the 3rd quarter worth about $1,689,000. Northern Trust Corp grew its holdings in shares of Guardant Health by 2.1% during the 3rd quarter. Northern Trust Corp now owns 1,103,688 shares of the company’s stock worth $32,713,000 after purchasing an additional 22,548 shares during the period. Finally, Eagle Asset Management Inc. purchased a new stake in shares of Guardant Health during the 3rd quarter worth about $8,248,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

GH stock opened at $29.56 on Monday. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. Guardant Health has a twelve month low of $15.81 and a twelve month high of $41.06. The company’s 50 day moving average is $23.71 and its two-hundred day moving average is $22.86. The stock has a market cap of $3.62 billion, a P/E ratio of -7.54 and a beta of 1.15.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The company had revenue of $168.49 million for the quarter, compared to analysts’ expectations of $150.51 million. Research analysts expect that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.